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George W Bush’s second term
Many domestic and international health policies are likely to be controversial
When George W Bush returns to the WhiteHouse after his inauguration ceremony,health is unlikely to be at the top of his
agenda. In the months ahead he must devise strategies
that will tackle record budget and trade deficits and
pave the way for an exit from an increasingly unpopu-
lar war in Iraq. Yet many of the other decisions that he
and his administration must make will have profound
consequences for the health of America’s people and
for those in many other countries.
That the American healthcare system is in a mess
has long been apparent. Despite spending vast and
ever increasing amounts of money (now over a third
more per person than Switzerland, the next highest
spender), uniquely among industrialised countries the
United States does not attempt to provide cover for all
its citizens, and the number of uninsured people has
increased from 42 million to 45 million in the past four
years. Although the country spends almost 15% of its
national income on health care, its outcomes are
appalling, with death rates among young people from
some common chronic diseases three or four times
higher than in European countries.1 The reforms that
are being proposed contain some potentially good
ideas, such as reform of the law on malpractice claims,
expansion of community health centres, and help for
small businesses to become more effective purchasers
of insurance.2 Others are seriously misguided, most
notably the concept of health savings accounts.
An individual enrolled in a health savings account
receives coverage for catastrophic illness. Other health
care must be paid first by the individual, up to a defined
limit (typically several thousand dollars), after which
they can draw on the tax free fund into which they and
their employer have paid. Any money in this fund that is
unspent at the end of the year is rolled over to provide,
hopefully, a reasonable pool for any future needs.
Accounts appeal to wealthy people, who are likely to
leave existing schemes.3 Those remaining will be dis-
proportionately poor and unhealthy4 and will face higher
premiums because of the loss of cross subsidy, which
will further increase the number of uninsured people.
Several other domestic policies are likely to prove
controversial. The expected change in the composition
of the Supreme Court will facilitate a review of the legal-
ity of abortion. Social policies will emphasise fundamen-
talist views on sexuality and family relationships,5 with
sex education based on the ineffective model of promot-
ing abstinence.6 As a consequence, the already high rate
of teenage pregnancies is likely to increase further.
The ability to respond to the challenges ahead will
be constrained by the growing politicisation of
American science. The Union of Concerned Scientists
has catalogued how the first Bush administration sought
to suppress or distort research deemed unhelpful or out
of line with its socially conservative policies.7 A congres-
sional committee has documented how this degree of
political interference is unprecedented in the United
States, noting that the consequences of this process go
far beyond the delivery of health care to affect policies
on education, the environment, and many other areas.8
As the United States is the one remaining global
superpower, policies adopted inWashington have impli-
cations for the world. The Bush administration has pur-
sued a sustained campaign against multilateralism,
seeking to block action on issues as diverse as global
warming and landmines. It has decided that the Geneva
conventions do not apply to some of its prisoners and
has refused to accept the authority of the International
Criminal Court. The United Nations has been subjected
to vitriolic attacks in the American media, and the Bush
administration has sought, where possible, to lead coali-
tions of the willing that bypass the UN and its specialised
agencies. An example is the President’s Emergency Plan
for AIDS Relief, which exists in parallel with, and
arguably undermines, the Global Fund to fight AIDS,
Tuberculosis, and Malaria by diverting needed
resources. The president’s emergency plan has been
slow in spending the money made available to it, and
much of what has been spent has been used to purchase
expensive patented drugs instead of cheaper generics.9
Such mechanisms are attractive to the administra-
tion as they provide a means of projecting domestic
policies on, for example, sexuality, to many other coun-
tries, a process aided by the global gag rule in which
any organisation receiving American government
funds must agree not to provide counselling for those
seeking abortion or lobby for its legalisation. Some
signs, however, show that the administration is review-
ing this approach as illustrated by its rapid abandon-
ment of the four country coalition created to provide
relief to the victims of the tsunami in the Indian Ocean.
Like other second term presidents George W Bush
will have one eye on his place in history. The greatest
epitaph for a politician is that they leave the world in a
better state than they found it. History will be the judge.
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Opioids for persistent non-cancer pain
A team approach and individualisation of treatment are needed
Epidemiological studies from Australia and Den-mark indicate that about 19% of the populationis afflicted by chronic pain that is not caused by
cancer.1 2 The prevalence of chronic pain that interferes
with daily activities is 12.6%.1 In most Western countries,
opioids are established in treating pain due to cancer,
and they are increasingly used to manage chronic pain
not due to cancer. Opioids are effective analgesics, but
they also have a strong reinforcing potential—fear of
addiction and diversion restrict their medicinal use.
Good clinical trials, guidelines, and responsible prescrip-
tion are needed to ensure the availability of opioids for
those patients who may benefit.3 4
A recent systematic review included 11 randomised
and controlled trials on oral opioids in non-cancer pain.5
The review showed that opioids provided pain relief for
both neuropathic (postherpetic neuralgia, diabetic neu-
ropathy) and musculoskeletal pain (osteoarthritis). Large
differences between individuals in the response to opioids
in all conditions implied that the effectiveness of the treat-
ment should be tested in each individual. Adverse effects
were common and included constipation, nausea,
vomiting, somnolence, sedation, dizziness, itching, dry
mouth, and headache. The studies were of short duration
(four days to eight weeks in each treatment arm). Some
studies included an open label phase for up to two years,
but only a few patients continued to use opioids.
When treating pain due to cancer, alleviating
symptoms is the main goal, whereas in the manage-
ment of chronic non-cancer pain the goal is to keep
the patient functional, both physically and mentally,
with improved quality of life. Relief of pain may be an
essential factor in this and opioids are only one aspect
of the overall rehabilitative strategy for the patient. In a
few instances, such as when an elderly patient is waiting
for a hip replacement, opioids can be regarded as a
fairly straightforward means of alleviating pain for a
limited period. The more chronic and complex the
problem and the younger the patient, the lesser is the
role opioids have in the rehabilitation plan. A multidis-
ciplinary pain clinic will try other analgesics (including
antidepressants and anticonvulsants), non-steroidal
anti-inflammatory drugs, weak analgesics, transcutane-
ous nerve stimulation, cognitive behaviour therapy,
and exercise programmes.
Opioids are not effective in every patient with pain.
Randomised controlled trials indicate that no criteria
have been identified that predict good response to
opioids in any particular condition. Also, these trials
were of short duration and included a selected group
of patients. Many questions regarding safety, such as
long term effects on hormonal and immune function,
development of tolerance and increased pain sensitiv-
ity, addiction and diversion of drugs were not answered
by these trials.6 Therefore, each patient who is
considered for treatment with opioids needs to be
assessed for both efficacy and safety. Good monitoring
serves the individual patient and provides valuable
information from areas that cannot be studied in ran-
domised and placebo controlled studies, such as toler-
ance, addiction, and diversion of drugs.
Patients need to be informed of the possible
benefits and risks of opioid treatment, and they need to
be monitored carefully. This takes time. Treatment of
young patients and patients with psychosocial prob-
lems or addictive behaviour should be initiated in
multidisciplinary pain clinics that have the resources
and expertise to assess these problems. However,
primary care doctors should always be involved in the
decision making as they will usually take responsibility
for the patients in the long term.Multidisciplinary pain
clinics should be available for consultation if problems
occur. These clinics should also follow and audit to
ensure that information gained over the years is used
to reassess the appropriateness of the treatment.
Opinions regarding the medicinal use of opioids
have always been polarised. History shows how too
liberal use has led to heightened regulatory control,
reluctance of doctors to prescribe opioids, and
under-treatment of pain. Guidelines are needed to
prevent history repeating itself. The British Pain
Society published its recommendations for the
appropriate use of opioids for persistent non-cancer
pain in March 2004.4 The document includes
information for the patient, who is an important part-
ner in the treatment plan. The recommendations were
carefully worked out with consultations of the royal
colleges of anaesthetists, general practitioners, and
psychiatrists. They are based on what is known about
the effectiveness of opioids in the treatment of chronic
non-cancer pain. The recommendations acknowledge
the lack of data in many important areas of clinical
research; in these areas they are based on clinical expe-
rience. The recommendations provide an excellent
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